Critical Contrast: NKGen Biotech (NYSE:NKGN) versus ZIVO Bioscience (NASDAQ:ZIVO)

Insider and Institutional Ownership

12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 48.9% of ZIVO Bioscience shares are held by insiders. Comparatively, 10.4% of NKGen Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares ZIVO Bioscience and NKGen Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
NKGen Biotech	N/A	N/A	-479.36%

Valuation & Earnings

This table compares ZIVO Bioscience and NKGen Biotech”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15,850.00	1,959.37	-$7.78 million	($2.18)	-3.67
NKGen Biotech	N/A	N/A	-$82.94 million	($1.72)	-0.01

ZIVO Bioscience has higher revenue and earnings than NKGen Biotech. ZIVO Bioscience is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

ZIVO Bioscience has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500.

Summary

NKGen Biotech beats ZIVO Bioscience on 5 of the 8 factors compared between the two stocks.

About ZIVO Bioscience

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

About NKGen Biotech

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.